Workshop “Diagnostics for reducing antimicrobial resistance (AMR)”

Agenda

19, June 2017 • Hotel Renaissance Parnasse
Rue du Parnasse 19 • 1050 Brussels • Belgium

Workshop objectives

- To consult with the relevant stakeholders on a potential Call for proposals under IMI2 addressing the topic ‘Diagnostics for reducing AMR’ that would aim at establishing a framework for value-based translation of innovative diagnostics into routine use to reduce AMR.
- To better understand the challenges and hurdles faced by diagnostic innovators for translation of early-stage products into validation, and value demonstration in primary and clinical healthcare practice.
- To obtain a better understanding of what evidence is needed from regulators, health technology assessment bodies and payers for implementation and adoption by healthcare systems.

08:00 – 09:00  Registration and networking breakfast

09:00 – 10:30  Session 1: Welcome & setting the scene

Session chair: Angela Wittelsberger, Innovative Medicines Initiative

9:00 – 9:05  A word of welcome (video message)
Pierre Meulien, Executive Director, Innovative Medicines Initiative

9:05 – 9:30  The Innovative Medicines Initiative: building new models of collaborative research
Angela Wittelsberger, Scientific Officer, Innovative Medicines Initiative

9:30 – 10:00  Diagnostics to address antimicrobial resistance
Mark Miller, Chief Medical Officer bioMérieux

10:00 – 10:30  The World Health Organisation’s view on in vitro diagnostics for addressing antimicrobial resistance
Francis Moussy, Lead for AMR Diagnostics, WHO

The Wellcome Trust’s view on in vitro diagnostics for addressing antimicrobial resistance
Timothy Jinks: Head - Wellcome Trust Drug Resistant Infections priority program

The European Commission’s view on in vitro diagnostics for addressing antimicrobial resistance
Arjon Van Hengel, DG Research & Innovation, European Commission

10:30 – 11:00  Coffee break
11.00–12:00  Session 2: Presentation of preliminary plans for a topic under the Innovative Medicines Initiative “Diagnostics in AMR”

Session chair: Mark Miller (bioMérieux)

Implementation of diagnostics, Volker Liebenberg (Thermo Fisher)
Where are the gaps towards a standardised care network?, Philippe Cleuziat (bioMérieux)
Design of a clinical study to demonstrate the value of diagnostics, Kieran Clarke (Alere)

12.00–12:30  Session 3: Round table “Value and challenges of diagnostics in clinical research”

Panellists: Hermann Goossens (University of Antwerp), Valerie D’Acremont (University Hospital of Lausanne), Trinad Chakraborty (Justus-Liebig University Giessen), Rosanna Peeling (London School of Hygiene and Tropical Medicine)

Moderator: Timothy Jinks, Wellcome Trust

12.30 – 14.00  Networking Lunch

14:00 – 15:30  Session 4: Flash presentations stakeholder perspectives

Stakeholder representatives should speak for maximum 5 min and are asked to address the following questions:
- What role should diagnostics play to address AMR from your perspective?
- What are the main gaps and challenges that should be addressed by a potential call topic under IMI to support the value of diagnostics?

Academia – Till Bachmann (University of Edinburgh)
Small- and medium-sized enterprise – Holger Becker (microfluidic chipchop GmbH)
IVD Regulator – Isabelle Beredjian-Ding (Paul-Ehrlich-Institute)
Health Technology Assessment – Sheryl Warttig (National Institute for Health and Care Excellence)
Civil society – Joe Thomas (The Pew Charitable Trusts)
– Khairunisa Suleiman (Consultant)
Clinical research – Jordi Vila (Hospital Clinic Barcelona)
MedTech industry – Yves Verboven (MedTech Europe)
Product Development Partnership – Jerome St. Denis (FIND)

Spontaneous interventions

15:30 – 16:00  Open floor discussion

Feed-back on the stakeholder perspectives

Moderators: Volker Liebenberg (Thermo Fisher) & Timothy Jinks (Wellcome Trust)

16:00 – 16:15  Summary, miscellaneous & next steps

Angela Wittelsberger, Innovative Medicines Initiative